A Critical Review of Current Worldwide Definitions of Sarcopenia.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert commentary without systematic review methodology or primary data
PubMed 38043100 · doi:10.1007/s00223-023-01163-3
What was done
The authors conducted a critical review analyzing existing international diagnostic frameworks and consensus definitions of sarcopenia. The review outlines key challenges, trade-offs, and methodological considerations involved in creating a standardized global diagnostic definition, with particular focus on the Global Leadership Initiative on Sarcopenia (GLIS).
What was found
The abstract reports no primary experimental data or statistical comparisons, though it notes that sarcopenia is estimated to affect approximately 13% of individuals worldwide. It describes ongoing efforts to resolve divergent regional diagnostic criteria to improve clinical management and research comparability.
Why it matters
Inconsistent diagnostic criteria across international working groups make prevalence comparisons difficult and hinder clinical trial design. Harmonizing the definition of sarcopenia is essential for establishing standardized diagnostic protocols, assessing prognostic risks, and determining optimal treatments.
Limits
This is a narrative review presenting expert commentary rather than a systematic review or meta-analysis. The abstract provides no primary empirical data, no quantitative comparisons between existing diagnostic thresholds, and no newly finalized consensus criteria.
Cited by
- supports Age-related muscle loss is called sarcopenia.